A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine bioequivalence of amodiaquine suspension ( Pfizer)
and the WHO approved reference product Flavoquine® tablet ( Sanofi Aventis).